Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir

Mogalian E, German P, Kearney BP, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. Clin Pharmacokinet. 2016;55(5):605-613.

Publication Type:

Journal Article

Authors:

Mogalian, E.; German, P.; Kearney, BP; et, al

Source:

Clin Pharmacokinet, Volume 55, Issue 5, p.605-613 (2016)

Cited On:

External Third-party Web Link:

https://www.ncbi.nlm.nih.gov/pubmed/26519191

Export Citation:

RIS Format

Top